

Supplemental Table 3.1. Standardized Mean Differences (SMD) After Propensity Score Matching

		Steroids (N = 1563)	Anti-TNF (N = 1563)	
Characteristic	Group	%	%	SMD
Age at index	1 = 18-34.9	28.0	24.8	0.07
	2 = 35-49.9	31.3	31.2	0.00
	3 = 50-64.9	15.3	15.6	0.01
	4 = 65-69.9	10.3	11.1	0.03
	5 = 70-74.9	7.6	8.6	0.04
	6 = 75-79.9	4.7	5.3	0.03
	7 = 80+	2.8	3.4	0.03
Gender	Female	65.4	65.3	0.00
Race	White	84.1	84.8	0.02
Calendar year at index	2001	9.1	8.3	0.03
	2002	8.5	7.7	0.03
	2003	6.7	6.4	0.01
	2004	7.3	7.2	0.00
	2005	5.6	6.0	0.02
	2006	2.5	2.5	0.00
	2007	11.5	12.2	0.02
	2008	10.0	10.6	0.02
	2009	10.5	10.2	0.01
	2010	9.2	9.4	0.01

		Steroids (N = 1563)	Anti-TNF (N = 1563)	
Characteristic	Group	%	%	SMD
	2011	9.7	9.3	0.01
	2012	9.4	10.4	0.03
Urban residence	Yes	69.4	69.2	0.00
Diabetes	Yes	10.9	11.6	0.02
Hypertension	Yes	27.2	28.3	0.02
Coronary artery disease	Yes	8.6	9.0	0.01
Congestive heart failure	Yes	3.0	3.6	0.03
Carotid artery disease	Yes	0.4	0.6	0.03
Hypercholesterolemia	Yes	18.9	20.0	0.03
Osteoporosis	Yes	11.2	12.3	0.03
Stroke/Parkinson's disease	Yes	1.3	1.4	0.01
Problems with balance	Yes	16.6	15.9	0.02
Falls in prior 365 days	Yes	0.1	0.1	0.00
DXA scan in prior 365 days	Yes	13.4	13.8	0.01
Combined comorbidity score	0 = ≤ 0	26.2	26.8	0.01
	1 = 1	22.8	23.3	0.01
	2 = 2-3	29.0	27.5	0.03
	3 = 4+	21.9	22.4	0.01
Fistula w/in 365 and 56 days prior to index	0 = none in past 365 days	68.1	68.9	0.02
	1 = w/in 57-365 days prior	17.9	17.9	0.00

		Steroids (N = 1563)	Anti-TNF (N = 1563)	
Characteristic	Group	%	%	SMD
	2 = w/in 56 days prior	14.1	13.2	0.03
Small bowel follow-through exam w/in 365 and 56 days prior to index	0 = none in past 365 days	72.0	72.0	0.00
	1 = w/in 57-365 days prior	18.2	18.1	0.00
	2 = w/in 56 days prior	9.9	9.9	0.00
Colonoscopy or sigmoidoscopy w/in 365 and 56 days prior to index	0 = none in past 365 days	41.6	42.8	0.02
	1 = w/in 57-365 days prior	38.1	37.2	0.02
	2 = w/in 56 days prior	20.3	20.0	0.01
CT or MRI scan of abdomen/pelvis w/in 365 and 56 days prior to index	0 = none in past 365 days	43.4	44.9	0.03
	1 = w/in 57-365 days prior	31.4	31.3	0.00
	2 = w/in 56 days prior	25.2	23.8	0.03
<i>C difficile</i> w/in 183 and 56 days prior to index	0 = none in past 183 days	98.1	98.2	0.01
	1 = w/in 57-183 days prior	1.1	1.2	0.01
	2 = w/in 56 days prior	0.8	0.6	0.02
Testing for <i>C difficile</i> w/in 183 and 56 days prior to index	0 = none in past 183 days	85.0	83.8	0.03
	1 = w/in 57-183 days prior	10.6	11.1	0.02
	2 = w/in 56 days prior	4.4	5.1	0.03
Ostomy w/in 183 days prior to index	Yes	9.1	9.2	0.00

		Steroids (N = 1563)	Anti-TNF (N = 1563)	
Characteristic	Group	%	%	SMD
Bowel resection w/in 183 days prior to index	Yes	3.4	3.3	0.01
Serious infection w/in 183 days prior to index	Yes	5.4	5.4	0.00
Opportunistic infection w/in 183 days prior to index	Yes	1.0	0.5	0.06
Blood transfusion w/in 183 days prior to index	Yes	5.4	5.4	0.00
Intravenous iron w/in 183 days prior to index	Yes	1.2	1.1	0.01
Parenteral nutrition w/in 183 days prior to index	Yes	3.3	3.3	0.00
Anemia from iron deficiency or NOS w/in 183 days prior to index	Yes	29.2	29.6	0.01
Other nutritional anemia (e.g., B12) w/in 183 days prior to index	Yes	5.5	5.7	0.01
Weight loss or malnutrition w/in 183 days prior to index	Yes	6.8	7.2	0.02
Dehydration/hypovolemia w/in 183 days prior to index	Yes	15.5	15.4	0.00
Electrolyte disorders w/in 183 days prior to index	Yes	16.8	15.5	0.04
Pyoderma gangrenosum w/in 183 days prior to index	Yes	0.8	0.8	0.00

		Steroids (N = 1563)	Anti-TNF (N = 1563)	
Characteristic	Group	%	%	SMD
Stool culture w/in 183 days prior to index	Yes	8.1	8.3	0.01
Quinolone Rx w/in 183 days prior to index	Yes	31.1	32.9	0.04
Metronidazole Rx w/in 183 days prior to index	Yes	30.9	29.6	0.03
Other antibiotic Rx w/in 183 days prior to index	Yes	43.8	42.9	0.02
Herpes antiviral Rx w/in 183 days prior to index	Yes	3.3	3.1	0.01
Antifungal Rx w/in 183 days prior to index	Yes	9.0	9.3	0.01
Mesalamine Rx w/in 183 days prior to index	Yes	53.6	53.7	0.00
AZA/6MP Rx w/in 183 days prior to index	Yes	34.1	34.4	0.01
Methotrexate Rx w/in 183 days prior to index	Yes	2.9	3.3	0.02
Narcotics Rx (excluding Belladonna/Opium) w/in 183 days prior to index	Yes	61.4	61.2	0.00
PPI Rx w/in 183 days prior to index	Yes	38.3	40.3	0.04
Benzodiazepine Rx w/in 183 days prior to index	Yes	13.3	12.4	0.03

		Steroids (N = 1563)	Anti-TNF (N = 1563)	
Characteristic	Group	%	%	SMD
Bisphosphonate Rx w/in 183 days prior to index	Yes	10.2	9.8	0.01
High dose vitamin D Rx w/in 183 days prior to index	Yes	0.1	0.3	0.04
Stains Rx w/in 183 days prior to index	Yes	10.1	11.5	0.05
Fibrates Rx w/in 183 days prior to index	Yes	3.6	3.1	0.03
Cumulative Prednisone equivalent dose in 183 days prior to index	0 = 0	26.1	27.4	0.03
	1 = < 10 mg/day	73.9	72.6	0.03
Cumulative Budesonide equivalent dose in 183 days prior to index	0 = 0	81.6	81.6	0.00
	1 = < 3 mg/day	18.4	18.4	0.00
# of non-IBD medication classes taking during 183 days prior to index	0-3	17.6	17.3	0.01
	4-6	27.2	27.6	0.01
	7-10	30.1	31.2	0.02
	> 10	25.1	24.0	0.03
Total IBD hospitalization days in 183 days prior to index	0 = none	58.5	59.1	0.01
	1 = ≥ 1day	41.5	40.9	0.01
# of hospitalizations other than IBD in 183 days prior to index	0	86.2	85.4	0.02
	1+	13.8	14.6	0.02

		Steroids (N = 1563)	Anti-TNF (N = 1563)	
Characteristic	Group	%	%	SMD
Index drug	Budesonide	23.2	0.0	
	Prednisone	76.8	0.0	
	Adalimumab	0.0	19.4	
	Certolizumab	0.0	5.1	
	Infliximab	0.0	75.5	